Skip to content

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NASH - Nonalcoholic Steatohepatitis | MASH - Metabolic Dysfunction-Associated Steatohepatitis

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 to 80

Participation Criteria

Inclusion Criteria:

* Cohort 1: Biopsy proven compensated cirrhosis (fibrosis stage 4) due to NASH/MASH
* Cohort 2: Biopsy proven or non-invasively diagnosed compensated cirrhosis (fibrosis stage 4) due to NASH/MASH

Exclusion Criteria:

* Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results
* Type 1 diabetes or unstable Type 2 diabetes
* Any current or prior history of decompensated liver disease

Other inclusion and exclusion criteria may apply

Study Location

Akero Clinical Study Site
Akero Clinical Study Site
Vaughan, Ontario
Canada

Contact Study Team

Primary Contact

Akero Site 0504

Akero Clinical Study Site
Akero Clinical Study Site
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Akero Site 0501

Akero Clinical Study Site
Akero Clinical Study Site
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Akero Site 0502

Study Sponsored By
Akero Therapeutics, Inc
Participants Required
More Information
Study ID: NCT06528314